Influence of Intestinal Transporter Genetic Variants on the Bioavailability of Gabapentin
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The current study is part of a large multi-investigator grant to look at the pharmacogenetics
of a number of membrane transporters. Previously, we have recruited a cohort of healthy
volunteers (Studies of Pharmacogenetics in Ethnically-diverse Populations, or SOPHIE) and
have resequenced the coding region of a number of membrane transporter genes to identify
genetic polymorphisms in these genes. We plan to take a genotype-to-phenotype approach to
study the influence of specific polymorphisms in the intestinal transporters, such as the
novel organic cation transporters 1 and 2 (OCTN1 and OCTN2) genes on the bioavailability of
gabapentin in healthy subjects. Eligible subjects will have a single inpatient study visit,
during which they will take a single dose of gabapentin, and provide blood and urine samples
over the course of 36 hours (5 terminal elimination gabapentin half-lives) for
pharmacokinetic analysis.